ClinTex is a clinical trials collaboration and data analytics platform that leverages the benefits of distributed ledger technology (blockchain). It uses smart contracts on the Ethereum public blockchain to provide an end to end decentralised solution that incorporates tools to drive collaboration in the sharing of clinical trial data across the industry and significant quality and operational improvements in running clinical trials through advanced clinical data review, insightful operational key performance indicators (KPIs), predictive data analytics and machine learning (AI). The ClinTex Clinical Trials Intelligence Platform (ClinTex CTi) will vastly improve pharmaceutical companies’ operational and clinical effectiveness in setting-up, conducting, overseeing, reviewing, and meeting regulatory standards for clinical trials. The foundation of the ClinTex CTi platform lies simultaneously in the creation of an ecosystem that enables interoperability of all clinical trial data views and, by using blockchain technology, the unique ability to deliver a secure environment for the storage and analysis of selected historical clinical data views. In this way, the ClinTex CTi platform provides the optimum environment to share clinical data views and develop data analytics solutions while addressing the privacy and security concerns of all stakeholders. Through the CTi platform, an ecosystem is created with seven separate decentralised applications. Together these applications will provide valuable clinical insight that leverages the use of novel predictive analytical tools and machine learning for the benefit of Clinical Project Managers, Clinical Trial Physicians, Clinical Data Managers, Pharmacovigilance staff and Site Monitors.
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3-Q4 2020
Verified 9%
Attention. There is a risk that unverified members are not actually members of the team
Verified 0%
Attention. There is a risk that unverified members are not actually members of the team
There is enough material to suggest that ClinTex is aiming to address a real need within the clinical trial field. Tokenomics for the project are straightforward with minimal bonuses applicable and a clear team vesting period. The acceptance of Binance coin in the ICO adds another level of interest and, although no partnership is stated or implied, investors may feel it increases the possibility of a future listing opportunity with the exchange.
Maybe most importantly, an able team is backed by experienced advisors and together they have shown the foresight to partner with useful allies within the blockchain arena and realm of medical services.
The downside column is much shorter but it should be noted that there is currently no working product and the roadmap suggests that some of the infrastructure will not be fully available until well into 2020 which could hamper uptake of the platform.
The whitepaper states that one of the reasons ClinTex ClinTex has partnered with Intellimed is that they will “…deploy the CTi platform in academic clinical research settings.”
This suggests that a firm footing for the initial launch of the platform has been established so it is the forward momentum of ClinTex, that includes expected on-boarding of other pharmaceutical companies in mid-2019, that contributors to the ICO will need to judge.
Given that they have first mover advantage in this particular specialised arena, the fundamentals appear to outweigh the minor concern and marks ClinTex as an ICO worthy of serious consideration.
